Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aleksandr Dekhtyar

Psychiatry Hoffman Estates, IL Medical Doctor

NPI 1851391155 CMS profile 265259

2500 W Higgins Rd, Suite 815, Hoffman Estates, IL 60169

Open in the dashboard

General payments

$4,782

159 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aleksandr Dekhtyar of Hoffman Estates, IL is reported in the CMS Open Payments database as having received $4,782 across 159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,600 8
2024 General $676 26
2023 General $557 22
2022 General $379 17
2021 General $642 31
2020 General $271 15
2019 General $656 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aleksandr Dekhtyar
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Aleksandr Dekhtyar were reported at $1,600. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Aleksandr Dekhtyar Psychiatry median Middle half National median
2019 $656 $184 $59–$605 $163
2020 $271 $119 $36–$372 $114
2021 $642 $143 $43–$576 $132
2022 $379 $153 $50–$590 $149
2023 $557 $170 $56–$651 $160
2024 $676 $179 $57–$673 $164
2025 $1,600 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $1,440 4 payments
  2. AbbVie, Inc. $1,224 49 payments
  3. Janssen Pharmaceuticals, Inc $474 26 payments
  4. Vanda Pharmaceuticals Inc. $363 14 payments
  5. Otsuka America Pharmaceutical, Inc. $339 19 payments
  6. Alkermes, Inc. $164 8 payments
  7. Lundbeck LLC $161 9 payments
  8. ACADIA Pharmaceuticals Inc $150 7 payments
  9. Indivior Inc. $124 4 payments
  10. Avanir Pharmaceuticals, Inc. $97 5 payments
  11. Other $245 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,382 158 payments
  2. Debt forgiveness $1,400 1 payment
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $1,400 1 payment
  2. VRAYLAR Neuroscience $1,061 43 payments
  3. HETLIOZ $363 14 payments
  4. FANAPT $363 14 payments
  5. ABILIFY MAINTENA $327 18 payments
  6. INVEGA SUSTENNA $266 14 payments
  7. VRAYLAR Neuroscience $217 10 payments
  8. SPRAVATO $208 12 payments
  9. REXULTI $167 9 payments
  10. NUPLAZID $150 7 payments
  11. Other $1,367 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

4,636

Median for Psychiatry: 574

Drug cost

$614,967

Median for Psychiatry: $27,624

Branded share of claims

18.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 14 $164,848
Austedo Xr Deutetrabenazine Brand 17 $116,240
Invega Sustenna Paliperidone Palmitate Brand 21 $65,999
Nuplazid Pimavanserin Tartrate Brand 12 $59,975
Vraylar Cariprazine Hcl Brand 27 $58,280
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 183 $26,183
Risperidone Er Risperidone Microspheres Brand 13 $23,012
Rexulti Brexpiprazole Brand 12 $19,525
Zyprexa Olanzapine Brand 26 $13,617
Effexor Xr Venlafaxine Hcl Brand 12 $9,029

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$205,770

Medicare's payments for the services billed

Medicare patients

341

Average age 75

Services billed

2,624

208 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 62%
Alzheimer's or dementia 46%
Diabetes 40%
Ischemic heart disease 35%
Chronic kidney disease 35%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $463
$463 27 —
FANAPT
  • Vanda Pharmaceuticals Inc. $93
$93 — —
HETLIOZ
  • Vanda Pharmaceuticals Inc. $93
$93 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $14
$14 12 —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record